Driving Innovation in Epigenetics: EpiCypher’s 2024 Impact in Chromatin Research | PR Newswire [Video]

, /PRNewswire/ — EpiCypher proudly celebrates a landmark year in 2024, with seven peer-reviewed publications and over 550 product citations showcasing our impact on chromatin research and drug development. These achievements reflects EpiCypher’s unwavering commitment to equipping genomic scientists and biomedical researchers with cutting-edge chromatin technologies, assays, and services.

“The quality of research generated through our CUTANA^™ CUT&RUN and CUT&Tag epigenomics assays and nucleosome substrates is remarkable,” said Michael-Christopher Keogh, PhD, Chief Scientific Officer at EpiCypher. “EpiCypher R&D has been incredibly productive this year, and we look forward to working with our customers and collaborators on new exciting applications in 2025.”

Manuscript Highlights

EpiCypher works with a variety of scientists spanning diverse fields of research, highlighting the influence of their technologies in the epigenetics field. Their scientists contributed to 16 different manuscripts in 2024, including seven published studies and two notable preprints. General themes and technological advances include:

• Reader CUT&RUNfor simultaneous profiling of co-occurring epigenomic features (collaboration …